Response Genetics, Inc. (NASDAQ: RGDX) today announced that it has
begun performing the MAGE-A3 gene expression screening assay for
GlaxoSmithKline´s (GSK) Phase III clinical trial of the
investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic
(ASCI) as adjuvant therapy in MAGE-A3 positive patients with stage IB,
II or IIIA Non-Small Cell Lung Cancer (NSCLC). These assays will be
performed in formalin-fixed paraffin-embedded tissue.
"We are pleased to be working with GlaxoSmithKline in support of
this important clinical trial," said Kathleen Danenberg, President and
CEO of Response Genetics. "This would be the largest clinical trial
ever conducted in lung cancer treatment and, with approximately 35 to
50 percent of early NSCLC expressing the MAGE-A3 tumor-specific
antigen, we are excited to be involved and to be providing our
biomarker analysis."
GSK has begun recruiting for a Phase III trial evaluating MAGE-A3
ASCI as adjuvant therapy in MAGE-A3 positive patients with NSCLC. With
a target of about 2,270 patients, the randomized, double-blind, and
placebo-controlled MAGRIT trial will enroll patients with stage IB, II
or IIIA resected NSCLC. This would be the largest clinical trial ever
conducted in lung cancer treatment. All patients participating in the
trial have cancers expressing a tumor-specific antigen, MAGE-A3, which
is present in approximately 35 to 50 percent of early NSCLC. The
primary endpoint of the trial is disease-free survival.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (NASDAQ: RGDX) is engaged in the
research and development of pharmacogenomic cancer diagnostic tests
based on its proprietary and patented technologies. RGI´s technologies
enable extraction and analysis of genetic information from genes
derived from tumor samples stored as formalin-fixed and paraffin
embedded specimens. RGI currently generates revenue primarily from the
sales of its proprietary analytical pharmacogenomic testing services
of clinical trial specimens to the pharmaceutical industry. The
company was founded in 1999 and its principal headquarters are located
in Los Angeles, California. For more information, please visit
www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press
release and the statements of representatives of Response Genetics,
Inc. (the "Company") related thereto contain or may contain, among
other things, certain forward-looking statements, within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation,
statements with respect to the Company´s plans, objectives,
projections, expectations and intentions, such as the ability of the
Company to analyze cancer samples, the potential for using the results
of this research to develop diagnostic tests for cancer, the
usefulness of genetic information to tailor treatment to patients, and
other statements identified by words such as "projects," "may,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans" or similar expressions. These
statements are based upon the current beliefs and expectations of the
Company´s management and are subject to significant risks and
uncertainties, including those detailed in the Company´s filings with
the Securities and Exchange Commission. Actual results, including,
without limitation, actual sales results, if any, or the application
of funds, may differ from those set forth in the forward-looking
statements. These forward- looking statements involve certain risks
and uncertainties that are subject to change based on various factors
(many of which are beyond the Company´s control). The Company
undertakes no obligation to publicly update forward- looking
statements, whether because of new information, future events or
otherwise, except as required by law.
